Registration No. 333-292056 As filed with the U.S. Securities and Exchange Commission on January 28, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONK, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Delaware 2844 83-2455880 to REGIS ...

Registration No. 333- As filed with the U.S. Securities and Exchange Commission on December 10, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BONK, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Delaware 2844 83-2455880 18801 ...

Product Development and Innovation - Bonk, Inc. launched the Sure Shot Dietary Supplement in December 2023, aimed at reducing blood alcohol content with 28 active ingredients [174][177]. - Clinical trials for the Sure Shot Dietary Supplement showed a statistically significant reduction in Blood Alcohol Content (BAC) with a p-value of 0.002, indicating effectiveness [183]. - The Sure Shot Dietary Supplement is manufactured in compliance with Good Manufacturing Practices (GMP) to ensure quality and safety [178]. - The company has conducted extensive informal research since 2010, involving hundreds of pre-clinical tests to refine the Sure Shot Dietary Supplement [185]. - The company has received a Notice of Allowance for a new patent related to the Sure Shot Dietary Supplement, indicating ongoing innovation and product development [196]. Financial Performance - Beverage sales for the three months ended September 30, 2025, reached $1,514,817, a significant increase from $110,213 in the same period in 2024, reflecting a growth of approximately 1,274% [205]. - For the nine months ended September 30, 2025, beverage sales totaled $1,601,866, compared to $519,793 in 2024, representing a growth of approximately 208% [213]. - The company reported a net loss of $33,581,216 for the three months ended September 30, 2025, compared to a net loss of $11,929,277 in 2024 [205]. - Total operating expenses for the three months ended September 30, 2025, were $17,215,566, compared to $11,348,320 in 2024, marking an increase of 52% [207]. - Total operating expenses for the nine months ended September 30, 2025, were $26,990,405, a decrease from $32,923,489 in 2024, indicating a reduction of 18% [215]. Acquisitions and Market Strategy - The company completed the acquisition of Yerbaé, a premium plant-based energy beverage company, on June 27, 2025, to enhance its presence in the functional beverage market [175][190]. - The company is exploring digital asset opportunities through a transaction with Bonk, aiming to integrate blockchain technologies into marketing strategies [176][189]. - The company aims to enhance consumer engagement through a Revenue Sharing Agreement, issuing shares in exchange for a percentage of gross revenue from LetsBonk.fun [195]. Cost and Revenue Analysis - Cost of sales for the three months ended September 30, 2025, was $1,480,760, up from $402,399 in 2024, indicating a rise of 268% due to increased revenues [206]. - Cost of sales for the nine months ended September 30, 2025, was $1,522,942, down from $2,549,099 in 2024, reflecting a decrease of 40% due to a one-time inventory write-off in 2024 [214]. Research and Development Expenses - Research and development expenses increased from $100,591 in 2022 to $1,637,117 in 2023, reflecting the company's commitment to product innovation [185]. Regulatory Environment - The company is subject to various regulations affecting the production and sale of its products, which could impact future operations and financial performance [198].

Acquisition and Product Development - Safety Shot Inc. completed the acquisition of the dietary supplement product Safety Shot from GBB Drink Lab, Inc. in August 2023, gaining ownership of various assets including intellectual property and trademarks[158]. - Safety Shot Inc. acquired Yerbaé, a premium energy beverage company, on June 27, 2025, to enhance its strategic growth in the functional beverage market[171]. - The company plans to expand its product offerings with a powdered stick pack version of the Sure Shot Dietary Supplement to cater to evolving consumer demands[161]. - The Sure Shot Dietary Supplement, launched in December 2023, is formulated to reduce blood alcohol content and contains 28 active ingredients classified as Generally Regarded As Safe (GRAS)[159]. - The company owns five patents related to the Sure Shot Dietary Supplement, with the most recent patent granted on December 3, 2024, covering the current version of the product[197]. Financial Performance - For the three months ended June 30, 2025, the company generated revenues of $44,948, a decrease of 93.7% compared to $710,240 for the same period in 2024[205]. - Revenues for the six months ended June 30, 2025 were $87,049, a significant decrease from $880,972 for the same period in 2024, attributed to a shift in focus towards the acquisition of Yerbaé and a new marketing strategy[211]. - The company reported a net income of $13,374,947 for the three months ended June 30, 2025, compared to a net loss of $8,274,094 in the same period of 2024[204]. - Net income for the six months ended June 30, 2025 was $8,048,014, a turnaround from a net loss of $23,948,765 in 2024, showcasing improved financial performance[210]. - Other income for the six months ended June 30, 2025 included an unrealized gain on equity investment of $18,190,351, contributing positively to overall income[215]. Expenses and Cost Management - Total operating expenses for the three months ended June 30, 2025 were $4,363,514, a reduction of 49.3% compared to $8,618,618 for the same period in 2024[206]. - Total operating expenses for the six months ended June 30, 2025 were $9,774,838, a reduction from $21,575,170 in 2024[212]. - Cost of sales for the three months ended June 30, 2025 was $21,070, down 95.8% from $504,528 in the prior year[205]. - Cost of sales for the six months ended June 30, 2025 was $42,182, down from $2,887,813 in 2024, primarily due to decreased revenues and a one-time inventory write-off of $1,649,473 in 2024[211]. - Marketing expenses for the three months ended June 30, 2025 were $863,620, significantly lower than $2,593,322 in the same period of 2024[207][208]. - Marketing expenses for the six months ended June 30, 2025 were $1,220,051, compared to $4,044,095 in 2024, reflecting a strategic reduction in marketing spend[213][214]. - Research and development expenses increased from $100,591 in 2022 to $1,637,117 in 2023, reflecting the company's commitment to product development[167]. - Research and development expenses for the three months ended June 30, 2025 were $6,517, down from $119,911 in the prior year[207][208]. - Research and development expenses for the six months ended June 30, 2025 were $15,522, significantly lower than $261,404 in 2024, indicating a shift in resource allocation[213][214]. - Legal and professional expenses for the three months ended June 30, 2025 were $1,413,402, compared to $1,879,774 in the same period of 2024[207][208]. - Legal and professional expenses for the six months ended June 30, 2025 were $3,563,638, down from $4,252,724 in 2024, reflecting cost management efforts[213][214]. - Stock-based compensation for the six months ended June 30, 2025 was $2,897,107, a significant decrease from $11,045,669 in 2024, indicating a reduction in equity compensation[213][214]. Future Strategies - The company is focusing on closing the acquisition of Yerbaé and implementing a new marketing strategy expected to increase revenues in Q3 2025[205]. - The company plans to implement a new marketing strategy in Q3 2025, which is expected to drive revenue growth moving forward[211]. - Manufacturing is outsourced to contract manufacturers in India and the US, with products shipped to third-party warehouses for distribution[169]. - The company primarily sells products through e-commerce platforms, including Amazon, focusing on customer experience and relationship management to drive loyalty[168]. Clinical Trials - Clinical trials conducted from January 29, 2024, to June 10, 2024, with 36 participants showed a statistically significant reduction in Blood Alcohol Content (BAC) with a p-value of 0.002[166]. Legal Matters - The Bigger Settlement Agreement, entered on January 20, 2025, involves payments totaling $375,000 and the issuance of convertible notes amounting to $5.25 million[172].

Business Acquisition and Product Development - Safety Shot Inc. completed the asset purchase of the dietary supplement product Safety Shot from GBB Drink Lab, Inc. in August 2023, gaining ownership of various assets including intellectual property and trademarks [124]. - The Sure Shot Dietary Supplement, launched in December 2023, is formulated to reduce blood alcohol content and contains 28 active ingredients classified as Generally Regarded As Safe (GRAS) [125]. - The company plans to expand its product line with new flavors and a powdered stick pack version of the Sure Shot Dietary Supplement [127]. - The company is focused on continuous improvement through innovation and has developed a substantial portfolio of intellectual property to address unmet market needs [135]. - The company owns five patents related to its Sure Shot Dietary Supplement, with the most recent patent granted on December 3, 2024, which covers the current version of the product [149]. Financial Performance - For the three months ended March 31, 2025, the company reported a net loss of $5,326,933 compared to a net loss of $15,674,671 for the same period in 2024, indicating a significant improvement in financial performance [165]. - Basic and diluted loss per share for the three months ended March 31, 2025, was $0.08, compared to $0.33 for the same period in 2024, showing a reduction in loss per share [166]. - The Company generated revenues of $42,101 for the three months ended March 31, 2025, a decrease of 75.3% compared to $170,732 in the same period of 2024 [187]. - Cost of sales for the three months ended March 31, 2025 was $21,112, significantly lower than $2,383,285 for the same period in 2024, reflecting a one-time inventory write-off of $1,744,714 in 2024 [186][187]. - Total operating expenses decreased to $5,411,325 for the three months ended March 31, 2025, down from $12,956,552 in the same period of 2024, indicating a reduction in operational costs [188]. - Research and development expenses were $9,005 for the three months ended March 31, 2025, compared to $141,493 for the same period in 2024, showing a significant reduction in R&D spending [176][189]. - The net loss for the three months ended March 31, 2025 was $5,326,933, a 66.1% improvement from the net loss of $15,674,671 in the same period of 2024 [193]. Legal and Financial Obligations - The company entered into a settlement agreement with Bigger Capital, agreeing to pay $375,000 and issue convertible notes totaling $5.25 million [136]. - The Secured Convertible Bigger Note has a principal amount of $1.75 million, maturing on December 31, 2026, with an interest rate of 9% per annum [137]. - The company is engaged in a liabilities settlement program with Silverback Capital Corporation, aiming to pay down $14,580,395.73 in debts by issuing freely trading securities [147]. - The company has committed to promptly filing a registration statement for shares equal to 150% of the shares initially issuable upon exercise of the Bigger Notes, to be filed within ten business days of the settlement agreement [146]. - The company has reserved approximately 23,000,000 shares as potential settlement shares for the liabilities settlement program, with a maximum of 15,000,000 shares to be issued without shareholder approval [148]. Market and Regulatory Environment - Sales primarily occur through e-commerce platforms, including Amazon, with investments directed towards customer experience and brand promotion [133]. - Manufacturing is outsourced to contract manufacturers in India and the US, ensuring adherence to formulation specifications and Good Manufacturing Practices (GMP) [134]. - The company is subject to various U.S. federal, state, and local regulations affecting the production and sale of its dietary supplement, including compliance with the Federal Food, Drug, and Cosmetic Act [150]. - The company is classified as an "emerging growth company," allowing it to take advantage of certain exemptions from various reporting requirements applicable to other public companies [160]. Shareholder and Stock Information - The weighted-average number of common shares outstanding increased from 47,435,503 in 2024 to 69,258,402 in 2025, reflecting a 46% increase in shares [165]. - Stock-based compensation for the three months ended March 31, 2025 was $1,985,376, a significant decrease from $8,090,534 in the same period of 2024 [189][191]. - The Company has not recognized an allowance for doubtful collections as of March 31, 2025, indicating a stable collection environment [170]. - Deferred tax assets as of March 31, 2025 were approximately $15,362,309, fully offset by a valuation allowance due to the lack of earnings history [175]. Future Plans and Strategies - The Company is focusing on the acquisition of Yerbae Brands Inc. and plans to implement a new marketing strategy in the second quarter of 2025 [187]. - Legal and professional expenses for the three months ended March 31, 2025 amounted to $2,150,236, compared to $2,382,950 in the same period of 2024, indicating a decrease in legal costs [189][191].

AMENDMENT NO. 3 TO REGISTRATION STATEMENT ON FORM S-1 Registration No. 333-284689 As filed with the U.S. Securities and Exchange Commission on April 16, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAFETY SHOT, INC. (Exact name of registrant as specified in its charter) Copies to: (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identificat ...

Registration No. 333-284689 As filed with the U.S. Securities and Exchange Commission on April 10, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO Delaware 2844 83-2455880 REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAFETY SHOT, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Numbe ...

Registration No. 333-284689 As filed with the U.S. Securities and Exchange Commission on April 4, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAFETY SHOT, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Del ...

Financial Performance - Safety Shot Inc. reported a net loss of $51.7 million for the year ended December 31, 2024, compared to a net loss of $15.1 million for the previous year, reflecting an increase in losses of approximately 243%[252]. - The Company reported a net loss of $49,409,632 for the year ended December 31, 2024, compared to a net loss of $15,083,041 for the year ended December 31, 2023[274]. - The net loss from continuing operations was $48,411,830 for the year ended December 31, 2024, compared to a net loss of $14,821,513 for the year ended December 31, 2023[266]. - Total operating expenses for the year ended December 31, 2024, were $39,611,915, up from $12,524,869 for the year ended December 31, 2023[268]. - Research and development expenses amounted to $271,719 for the year ended December 31, 2024, compared to $100,591 for the year ended December 31, 2023[260]. - Other income for the year ended December 31, 2024, included $1,193,666 in realized gains on the sale of marketable securities and $6,567,092 in other income[271]. - The Company incurred legal and professional expenses of $8,063,858 for the year ended December 31, 2024, primarily related to due diligence and legal work on a proposed merger[269]. - The Company had losses from discontinued operations of $997,802 for the year ended December 31, 2024, compared to $261,528 for the year ended December 31, 2023[273]. - The Company has fully offset its deferred tax asset of approximately $14,660,582 for the year ended December 31, 2024, due to a valuation allowance[259]. Product Development and Sales - The company launched its e-commerce sales of the Safety Shot Beverage in December 2023, following the acquisition of the product and related assets in August 2023[230]. - The Safety Shot Beverage is formulated with 28 active ingredients and is designed to reduce blood alcohol accumulation, adhering to Good Manufacturing Practices (GMP)[231][233]. - The company plans to relaunch its Photocil product in the U.S. in Q4 2024, following FDA approval, with sales expected through e-commerce channels[237]. - Safety Shot Inc. is focusing on expanding its product line, including a powdered stick pack version of the Safety Shot Beverage and other health-related products such as hair loss treatments and sexual wellness products[234]. - The Company generated revenues of $701,967 for the year ended December 31, 2024, compared to $202,670 for the year ended December 31, 2023, representing a significant increase due to the commencement of marketing and selling its Safety Shot beverage in December 2023[267]. Financial Structure and Risk Management - The weighted average number of common shares outstanding increased from 30.9 million in 2023 to 54.4 million in 2024, impacting the loss per share calculation[252]. - The company has no current concentration risk or dependence on major customers, maintaining a diverse network of suppliers for its production processes[237][238]. - The financial statements are prepared in accordance with U.S. GAAP, with significant accounting policies including revenue recognition based on the transfer of control of goods to customers[241][242]. - The Company is in commercialization mode while continuing to pursue the development of its next generation products and new products[277]. Regulatory and Market Changes - Safety Shot Inc. has ceased marketing and selling CBD products due to regulatory changes and declining popularity, seeking to dispose of related assets[239].

Registration No. 333- As filed with the U.S. Securities and Exchange Commission on February 4, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 REGISTRATION STATEMENT ON FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SAFETY SHOT, INC. (Exact name of registrant as specified in its charter) (State or jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification No.) Delaware 2844 83-2455880 ...